SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is fueling a market rebound after a robust earnings report highlighted accelerating Azure growth and disciplined capital expenditure, easing long-standing investor concerns about AI infrastructure costs. Community sentiment is sharply divided between bullish traders betting on a sustained rally fueled by short-covering and cautious bears warning of potential profit-taking and technical resistance.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is seeing heavy community debate as investors weigh strong operational execution, record-breaking ABS issuance, and insider buying against macro headwinds and short-seller volatility. While bulls point to the company's AI-driven platform and consistent earnings beats as evidence of massive upside, bears remain focused on interest rate sensitivity and the stock's challenging technical history.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is seeing significant volatility as investors weigh disappointing earnings guidance and faster-than-expected revenue declines from Apple against long-term growth opportunities in AI and data centers. The community is actively debating the company's transition away from handset reliance, with some calling for patience as the business diversifies into automotive and IoT, while others remain critical of the recent margin pressures and downward analyst revisions.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is experiencing intense volatility as investors weigh persistent geopolitical tensions and rising Treasury yields against Microsofts resilient earnings and ongoing AI infrastructure spending. The community is actively debating whether recent price swings signal a fundamental market shift or a tactical opportunity for dip-buying amid broader concerns over interest rate policies and potential global economic instability.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is seeing intense community discussion following a mixed securities shelf offering, which some investors fear signals upcoming dilution while others view it as a strategic move to provide financial flexibility for pipeline development. The conversation remains heavily focused on the anticipation of Phase 3 maintenance data and the potential for a partnership or buyout, as traders debate whether the stock's current volatility is a buying opportunity or a warning sign of further downside.

iShares Trust - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

The iShares 20+ Year Treasury Bond ETF (TLT) is experiencing heightened volatility as investors grapple with a combination of persistent inflation concerns, rising crude oil prices due to geopolitical tensions in the Strait of Hormuz, and hawkish signals from Fed officials suggesting potential interest rate hikes. Community sentiment is deeply divided, with some investors betting on a long-term bottom for bonds amidst expectations of a structural economic breakdown, while others warn that higher yields and inflationary pressures will continue to pressure the fund's duration.

Rolls-Royce Holdings Plc designs, develops, manufactures, and services integrated power systems for use in the air, on land, and at sea. The company operates its business through following segments: Civil Aerospace, Power Systems, Defense and New Markets. The Civil Aerospace segment offers commercial aero engines and aftermarket services. The Power Systems segment includes engines, power systems and nuclear systems for civil power generation. The Defense segment consists of military aero engines, naval engines, submarines and aftermarket services. The New Markets segment includes development, manufacture and sales of small modular reactors (SMRs) and new electrical power solutions. The company was founded in March 1906 and is headquartered in London, the United Kingdom.

Rolls-Royce Holdings Plc - ADR

Rolls-Royce is seeing strong momentum as investors weigh a series of positive catalysts, including major defense contract optimism, raised analyst price targets, and the company's leading role in the burgeoning small modular reactor (SMR) market. The community is actively discussing the firm's robust operational turnaround and its potential to capture significant market share in the rapidly expanding data center power and next-generation aviation sectors.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending following the UAE's marketing authorization of Anktiva for both bladder and lung cancer, a significant expansion of its global footprint that investors are betting will bolster upcoming earnings. Community sentiment remains polarized, with many longs pointing to this global expansion and strong sales commentary as evidence of a coming reversal, while others remain frustrated by persistent short interest and the lack of a major domestic partnership announcement.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Cloud Memory Business Unit (CMBU), Core Data Center Business Unit (CDBU), Mobile and Client Business Unit (MCBU), and Automotive and Embedded Business Unit (AEBU). The CMBU segment focuses on memory solutions for large hyperscale cloud customers and High-Bandwidth Memory for all data center customers. The CDBU segment is involved in memory solutions for mid-tier cloud, enterprise, and OEM data center customers and storage solutions for all data center customers. The MCBU segment focuses on memory and storage solutions for the mobile and client segments. The AEBU segment is involved in memory and storage solutions for the automotive, industrial, and consumer segments. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is experiencing extreme volatility as investors weigh record-breaking earnings and strong AI-driven memory demand against concerns over semiconductor industry cycles and macroeconomic headwinds. The community is sharply divided, with bulls pointing to the company's long-term strategic importance in AI infrastructure while bears highlight recent capitulation patterns and potential risks from broader sector de-leveraging.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

Arm Holdings is currently experiencing high volatility as investors weigh strong long-term AI-driven compute demand against concerns over stretched valuations and recent analyst downgrades. The community is actively debating whether the stock's recent price swings represent a healthy consolidation for a long-term winner or a broader correction in the overheated semiconductor sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Bausch Health (BHC) Q2 Earnings and Revenues Beat Estimates

Bausch (BHC) delivered earnings and revenue surprises of +31.25% and +7.62%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Bausch (BHC) Reports Q2 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Bausch (BHC) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

BAUSCH HEALTH ANNOUNCES SECOND QUARTER 2026 RESULTS, RAISES GUIDANCE

BAUSCH HEALTH ANNOUNCES SECOND QUARTER 2026 RESULTS, RAISES GUIDANCE BAUSCH HEALTH ANNOUNCES SECOND QUARTER 2026 RESULTS, RAISES GUIDANCE PR Newswire LAVAL, QC, July 29, 2026 Second Quarter Consolidated Revenues of $2.85 billion, up 13% on a Reported basis and 11% on an Organic (non-GAAP)1 basis...

Bausch Health to Announce Second Quarter 2026 Results on July 29, 2026

Bausch Health to Announce Second Quarter 2026 Results on July 29, 2026 Bausch Health to Announce Second Quarter 2026 Results on July 29, 2026 PR Newswire LAVAL, QC, July 7, 2026 LAVAL, QC, July 7, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release second quarter 2026...

Michael Goettler Resigns from Bausch Health's Board of Directors

Michael Goettler Resigns from Bausch Health's Board of Directors Michael Goettler Resigns from Bausch Health's Board of Directors PR Newswire LAVAL, QC, July 1, 2026 LAVAL, QC, July 1, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that Michael Goettler has...

Bausch Health Companies Enters Oversold Territory (BHC)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me...

Bausch (BHC) Down 5.4% Since Last Earnings Report: Can It Rebound?

Bausch (BHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Bausch Health's Aesthetic Business, Solta Medical, Earns Prestigious Trademark Certification of Thermage in China

Bausch Health's Aesthetic Business, Solta Medical, Earns Prestigious Trademark Certification of Thermage in China Bausch Health's Aesthetic Business, Solta Medical, Earns Prestigious Trademark Certification of Thermage in China PR Newswire LAVAL, QC, May 28, 2026 Thermage, a pioneer in non-invasive...

Bausch Health Announces 2026 Annual Meeting of Shareholder Results

Bausch Health Announces 2026 Annual Meeting of Shareholder Results Bausch Health Announces 2026 Annual Meeting of Shareholder Results PR Newswire LAVAL, QC, May 19, 2026 LAVAL, QC, May 19, 2026...

Bausch Health to Participate in Barclays 30th Annual Leveraged Finance Conference

Bausch Health to Participate in Barclays 30th Annual Leveraged Finance Conference Bausch Health to Participate in Barclays 30th Annual Leveraged Finance Conference PR Newswire LAVAL, QC, May 12, 2026...

$BHC Q2 &#39;26 Earnings Results &amp; Recap

• Reported GAAP EPS of $0.69 up 72.50% YoY
• Reported revenue of $2.01B down -20.66% YoY
• Bausch Health Companies Inc. raised its full-year 2026 guidance, now targeting consolidated revenues of $10.790-$11.040 billion, Adjusted EBITDA of $4.050-$4.175 billion, and Adjusted Cash Flows from Operations of $1.400-$1.475 billion.

Stocktwits

Bausch Health Companies Inc

 Q2 '26 Earnings Results & Recap

• Reported GAAP EPS of $0.69 up 72.50% YoY
• Reported revenue of $2.01B down -20.66% YoY
• Bausch Health Companies Inc. raised its full-year 2026 guidance, now targeting consolidated revenues of $10.790-$11.040 billion, Adjusted EBITDA of $4.050-$4.175 billion, and Adjusted Cash Flows from Operations of $1.400-$1.475 billion.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada.

BHC Stock Plummets On Failed Liver Cirrhosis Trial: Retail Says ‘Lost Battle But Not The War’

Equity

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

BHCBausch Health Companies Inc

Fundamentals

Latest BHC News